Publication date: Jul 29, 2025
In the context of public health, asymptomatic carriers of respiratory infectious diseases are considered a hidden yet critical factor in the transmission of infection and represent a key target for efforts to mitigate disease spread. To contribute a unique genomic resource to the SARS-CoV-2 research community, we collected SARS-CoV-2-positive samples from asymptomatic individuals at the SB Coronavirus Inspection Center Corp. during the COVID-19 pandemic in Japan and conducted a comprehensive analysis of their viral genomes. Using Illumina COVIDSeq technology, we successfully generated 8,266 SARS-CoV-2 genome assemblies, all of which have been made publicly available to facilitate further research. In this report, we summarize our efforts to collect SARS-CoV-2-positive samples from asymptomatic individuals and highlight the key features and accessibility of this genomic dataset.
| Concepts | Keywords |
|---|---|
| Biotech | Asymptomatic |
| Japanese | Cov |
| Kingfisher | Doi |
| Pathogenicity11 | Genome |
| Https | |
| Individuals | |
| International | |
| Japan | |
| July | |
| Medrxiv | |
| Org | |
| Positive | |
| Preprint | |
| Sars | |
| Version |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infectious diseases |
| disease | MESH | infection |
| disease | MESH | COVID-19 pandemic |
| disease | IDO | facility |
| disease | IDO | country |
| drug | DRUGBANK | Methionine |
| disease | IDO | infectivity |
| disease | IDO | virulence |
| drug | DRUGBANK | Guanidine |
| disease | IDO | process |
| drug | DRUGBANK | Water |
| disease | IDO | reagent |
| disease | IDO | nucleic acid |
| disease | IDO | pathogen |
| disease | IDO | host |
| disease | IDO | history |
| disease | IDO | protein |
| disease | IDO | quality |
| disease | MESH | mutation rates |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | Influenza |